New Delhi News

Nasal Polyposis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Novartis, AstraZeneca, Amgen, Keymed Biosciences, GSK

 Breaking News
  • No posts were found

Nasal Polyposis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Novartis, AstraZeneca, Amgen, Keymed Biosciences, GSK

May 01
21:29 2023
Nasal Polyposis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight |  Key Companies - Novartis, AstraZeneca, Amgen, Keymed Biosciences, GSK
DelveInsight’s “Nasal Polyposis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nasal Polyposis.

DelveInsight’s “Nasal Polyposis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Nasal Polyposis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nasal Polyposis Market Forecast

 

Some of the key facts of the Nasal Polyposis Market Report: 

  • The Nasal Polyposis market size was valued approximately USD 1,531 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total prevalent cases of CRS in the 7MM were found to be 69,550,461 cases in 2021, which are expected to increase at a CAGR of 0.44% during the study period (2019─2032)
  • The 7MM accounted for 4,358,603 diagnosed prevalent cases of Nasal Polyposis in 2021, which are expected to increase during the study period (2019─2032). As per our analysis, 25% of the total diagnosed prevalent cases of CRS develop NP in the United States
  • In 2021, the EU-5 accounted for 1,982,824 diagnosed prevalent cases of Nasal Polyposis, which was 45% of the total diagnosed prevalent cases of Nasal Polyposis in the 7MM
  • Key Nasal Polyposis Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Allakos Inc., Idorsia Pharmaceuticals Ltd., Optinose US Inc., Novartis, Keymed Biosciences Co.Ltd, Hoffmann-La Roche, Knopp Biosciences, and others
  • Key Nasal Polyposis Therapies: FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Dupilumab, Mometasone furoate, AK001, ACT-774312, Fluticasone Propionate, OPN-375, Fevipiprant, CM310, Omalizumab, dexpramipexole, and others
  • The Nasal Polyposis epidemiology based on gender analyzed that out of the total diagnosed prevalent cases of Nasal Polyposis in the EU-5 countries (Germany, France, Italy, Spain and the United Kingdom) about 60% were male
  • The Nasal Polyposis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nasal Polyposis pipeline products will significantly revolutionize the Nasal Polyposis market dynamics.

 

Nasal Polyposis Overview

Nasal polyposis (NP) is small, benign (noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. These polyps tend to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections.

 

Get a Free sample for the Nasal Polyposis Market Report –

https://www.delveinsight.com/sample-request/nasal-polyposis-market

 

Nasal Polyposis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Nasal Polyposis Epidemiology Segmentation:

The Nasal Polyposis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Nasal Polyposis
  • Prevalent Cases of Nasal Polyposis by severity
  • Gender-specific Prevalence of Nasal Polyposis
  • Diagnosed Cases of Episodic and Chronic Nasal Polyposis

 

Download the report to understand which factors are driving Nasal Polyposis epidemiology trends @ Nasal Polyposis Epidemiology Forecast

 

Nasal Polyposis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nasal Polyposis market or expected to get launched during the study period. The analysis covers Nasal Polyposis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Nasal Polyposis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Nasal Polyposis Therapies and Key Companies

  • FASENRA (benralizumab): AstraZeneca
  • Tezepelumab: AstraZeneca/ Amgen
  • CM310: Keymed Biosciences
  • GSK3511294 (depemokimab): GlaxoSmithKline
  • Dupilumab: Sanofi
  • Mometasone furoate: Regeneron Pharmaceuticals
  • AK001: Allakos Inc.
  • ACT-774312: Idorsia Pharmaceuticals Ltd.
  • Fluticasone Propionate: Optinose US Inc.
  • OPN-375: Optinose US Inc.
  • Fevipiprant: Novartis
  • CM310: Keymed Biosciences Co.Ltd
  • Omalizumab: Hoffmann-La Roche
  • dexpramipexole: Knopp Biosciences

 

Discover more about therapies set to grab major Nasal Polyposis market share @ Nasal Polyposis Treatment Market

 

Nasal Polyposis Market Drivers

  • Approval of pipeline drugs in the forecasted period
  • Rising prevalence
  • Increased approvals from regulatory bodies
  • Global exposure

 

Nasal Polyposis Market Barriers

  • Nasal Polyposis Misdiagnosis
  • Tools to define disease severity not defined well
  • Lack of cost-effective treatment
  • Lack of robust clinical pipeline
  • Limited awareness on Nasal Polyposis

 

Scope of the Nasal Polyposis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Nasal Polyposis Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Allakos Inc., Idorsia Pharmaceuticals Ltd., Optinose US Inc., Novartis, Keymed Biosciences Co.Ltd, Hoffmann-La Roche, Knopp Biosciences, and others
  • Key Nasal Polyposis Therapies: FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Dupilumab, Mometasone furoate, AK001, ACT-774312, Fluticasone Propionate, OPN-375, Fevipiprant, CM310, Omalizumab, dexpramipexole, and others
  • Nasal Polyposis Therapeutic Assessment: Nasal Polyposis current marketed and Nasal Polyposis emerging therapies
  • Nasal Polyposis Market Dynamics: Nasal Polyposis market drivers and Nasal Polyposis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Nasal Polyposis Unmet Needs, KOL’s views, Analyst’s views, Nasal Polyposis Market Access and Reimbursement 

 

To know more about Nasal Polyposis companies working in the treatment market, visit @ Nasal Polyposis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Nasal Polyposis Market Report Introduction

2. Executive Summary for Nasal Polyposis

3. SWOT analysis of Nasal Polyposis

4. Nasal Polyposis Patient Share (%) Overview at a Glance

5. Nasal Polyposis Market Overview at a Glance

6. Nasal Polyposis Disease Background and Overview

7. Nasal Polyposis Epidemiology and Patient Population

8. Country-Specific Patient Population of Nasal Polyposis 

9. Nasal Polyposis Current Treatment and Medical Practices

10. Nasal Polyposis Unmet Needs

11. Nasal Polyposis Emerging Therapies

12. Nasal Polyposis Market Outlook

13. Country-Wise Nasal Polyposis Market Analysis (2019–2032)

14. Nasal Polyposis Market Access and Reimbursement of Therapies

15. Nasal Polyposis Market Drivers

16. Nasal Polyposis Market Barriers

17.  Nasal Polyposis Appendix

18. Nasal Polyposis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services